GLP-1s changed metabolic care, but are not permanent solutions. A @WashingtonPost article, featuring our CEO and co-founder @HarithR, discusses how Fractyl Health is moving toward gene therapy for obesity and type 2 diabetes. Read more: washingtonpost.com/health/20…

At Fractyl Health, our team is driven by a shared mission: to transform care for people living with obesity and type 2 diabetes through durable, impactful innovation. This month, we’re proud to spotlight Lindsay Dee, Legal Operations Manager & Senior Paralegal, whose commitment to advancing meaningful change reflects the heart of our work. “I hope people living with obesity can access treatments that really work; ones that go beyond managing symptoms to help them feel healthy and confident again. I believe in a future where obesity care supports lasting wellbeing, even amid busy lives.” We’re grateful for Lindsay and for every member of our team who brings this purpose to life every day. #FractylForward #TeamFractyl

We are pleased to share new 6-month open-label data from the REVEAL-1 Cohort, marking another important milestone in our pursuit of innovative, durable solutions for people living with #metabolicdisease. The findings reinforce an encouraging trend: Revita® may help individuals maintain their weight after discontinuing GLP-1 drugs, underscoring the potential for longer-lasting metabolic control in #obesity. Thank you to our participants, investigators, partners, and the Fractyl team for advancing this important work. Read more about the data: ir.fractyl.com/news-releases… *Revita® is for Investigational Use Only in the U.S. under Federal law* #FractylForward

#News for #Investors and #Media: At 3 months, Revita® patients lost an additional 2.5% of total body weight after stopping GLP-1 therapy, while sham patients regained 10% (p=0.014). These randomized, blinded data support the potential for Revita to be the first therapy for post-GLP-1 weight maintenance. Watch the results below and read the full press release: ir.fractyl.com/news-releases… #ObesityCare #WeightLoss #GLP1 #Revita *Revita® is for Investigational Use Only in the U.S. under Federal law*

Fractyl Health (NASDAQ: $GUTS) today announced positive early data from the REVEAL-1 cohort of the ongoing REMAIN-1 pivotal study. Results show that the Revita® procedure – designed to address a root cause of obesity – has the potential to prevent weight regain after GLP-1 drug discontinuation. With GLP-1 adoption surging and discontinuation rates rising, these data point to a significant, under-addressed commercial opportunity: providing a scalable, non-pharmacologic solution to sustain weight loss without chronic drug use. Learn more: bit.ly/4hP1Mih #FractylForward #Obesity #ClinicalTrial #DataAnnouncement *Revita is for Investigational Use Only in the US under Federal law*

Extra-wide spectator seating. Bariatric ambulances. Oversized coffins. With more than half of the world’s population expected to have obesity by 2050, this @guardian article paints a sobering picture of how stadiums, hospitals, airlines and other industries are adapting to the global obesity emergency. theguardian.com/society/2025…… But what if we could change this trajectory by reversing obesity rather than accommodating it? We can imagine a world where all this is possible. The progress made with GLP-1 drugs has allowed one massive step in that direction. Our work at Fractyl Health aims to solve the problem by allowing people to live their lives at a lower weight – freely. #Obesity #HealthInnovation #AskAQuestionDay #FractylForward

Did you know that #obesity disproportionately impacts women? Nearly 42% of adult women in the U.S. live with obesity, placing them at increased risk for conditions like #heartdisease, #diabetes, and certain #cancers. Raising awareness and advancing solutions are essential steps towards improving women’s health outcomes. Women are the foundation of families and communities, often juggling multiple roles as professionals, caregivers and leaders. Their health and well-being are crucial – not just for themselves, but for society overall. When women thrive, communities flourish. Research, advocacy, and access to effective treatments all play a role in addressing this public health crisis. At Fractyl, we’re breaking the pattern of obesity treatment by addressing the root cause of this disease, to help ensure that women have the support they need to take charge of their health. #FractylForward #IWD2025 #WomensHistoryMonth #ObesityAwareness #WomenInHealth

UPCOMING: We’re pleased to share our Q4 and full year 2024 #earnings on Monday, March 3, at 4:30 PM ET. Join us for the live webcast: bit.ly/3D1KikB #NASDAQ: $GUTS #FractylForward

BREAKING: We're excited to announce promising initial clinical results from the first patient in the REVEAL-1 open-label cohort of our REMAIN-1 study. We're seeing positive results after one month of #GLP1 drug discontinuation alongside the Revita procedure, in line with trends observed in prior Revita clinical studies. Additionally, we're reporting significant progress in our REMAIN-1 pivotal study, evaluating weight maintenance after GLP-1 discontinuation. With more than 100 patients enrolled across the first 8 clinical study sites in less than 4 months since first site activation, this milestone reflects strong engagement from both #patients and #physicians. Read more about today's announcements: bit.ly/40u8Hbl $GUTS #FractylForward #ObesityData #Obesity

We look forward to connecting with industry peers and learning about the latest insights in #healthcare at @jpmorgan’s 43rd Annual Healthcare Conference in San Francisco! We hope to see you there. $GUTS #FractylForward #JPM2025

We’ve had a banner year at Fractyl Health. From going public, to presenting compelling data across the country to investors and scientists and receiving a Breakthrough Device designation from the FDA - we're celebrating our successes and looking #FractylForward to a big 2025 full of critical catalysts. We're deeply appreciative of our employees, our Board, our investors, our physician partners, and most importantly our patients for propelling us forward each day and making significant strides in the fight against #obesity and #T2D. We look forward to continuing this momentum in 2025!

We presented exciting new #Rejuva data at @WCIRDC last week. Thank you to all who attended our session. We hope to continue sharing this compelling data with our community! *Rejuva is in preclinical development and has yet to be assessed by regulatory agencies. $GUTS #FractylForward #WCIRDC24

We’re living our passion of developing breakthrough therapies to improve lives every day. See how Krysta Banfield, Diabetes Educator, finds innovative solutions for people living with #obesity and #T2D. #FractylForward

We’re breaking the pattern of #obesity and #T2D. Read more about Fractyl Health’s (#NASDAQ: $GUTS) Q3 financial results and our potentially novel approach to weight maintenance here: bit.ly/4hMqGR2 #FractylHealthNews

We were thrilled to share our latest research at @ObesityWeek and connect with brilliant minds dedicated to tackling #obesity and #T2D. Thank you to everyone who joined our presentations and engaged in insightful discussions! Read more: bit.ly/3AkC1aa #OW2024